Neurofibromatosis Type 2 Market Insight, Epidemiology and Market Forecast - 2034The Neurofibromatosis Type 2 treatment market is experiencin ...

A promising experimental drug is one more sign of the impending disruption the booming Chinese biotech industry could bring ...

Anselamimab, which AstraZeneca acquired via Caelum Biosciences, missed its primary goal in two late-stage trials, but appeared to have some benefit in a subgroup of patients.

The antibody anselamimab, which AstraZeneca picked up in its 2021 purchase of Caelum Biosciences, failed to improve survival and reduce hospitalizations, but the company sees promise in data from an ...

An experimental AstraZeneca (NASDAQ:AZN) drug, anselamimab, failed to extend survival or cut heart-related hospitalizations in patients with a rare plasma cell disorder, disappointing hopes it could ...

AstraZeneca’s plans to get an amyloidosis drug to market look further out of reach after the pharma’s anti-fibril antibody failed to reduce deaths and hospitalizations in a key phase 3 study. | ...

AstraZeneca on Wednesday said that its experimental drug anselamimab did not meet the main goal of a late-stage study for the treatment of AL amyloidosis, a rare condition that causes a buildup of ...

Anselamimab is a light chain depleter antibody which aims to treat light chain amyloidosis, a rare systemic and progressive disorder caused by defective plasma cells in bone marrow. The disease can ...

AstraZeneca said its amyloidosis treatment anselamimab failed to reach its primary goal in a final-stage trial.

AstraZeneca on Wednesday said that its experimental therapy anselamimab did not meet the main goal of a late-stage study for ...

True transformation requires AI that links customer data, knowledge bases, and operational systems to enable intelligent ...

Clever Culture’s APAS is now on trial with Novo Nordisk, and if it delivers, this one machine could unlock a global pharma ...